<DOC>
	<DOCNO>NCT02926768</DOCNO>
	<brief_summary>CK-101 novel , potent , small molecule tyrosine kinase inhibitor ( TKI ) selectively target mutant form epidermal growth factor receptor ( EGFR ) spar wild-type ( WT ) EGFR . The purpose study evaluate pharmacokinetic ( PK ) safety profile oral CK-101 ; determine maximum tolerate dose ( MTD ) and/or recommend Phase 2 dose ( RP2D ) oral CK-101 ; assess safety efficacy CK-101 previously treat NSCLC patient know T790M EGFR mutation .</brief_summary>
	<brief_title>Phase I/II Study CK-101 NSCLC Patients Other Advanced Solid Tumors</brief_title>
	<detailed_description>This first-in-human , two-part , open-label , safety , pharmacokinetic , efficacy study oral CK-101 administer daily ascend dos patient advance solid tumor cancer , follow Phase 2 portion recommend Phase 2 dose ( RP2D ) previously treat non-small cell lung cancer ( NSCLC ) patient document evidence EGFR T790M mutation fail treatment first-line EGFR inhibitor .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Diagnosis histologically confirm nonsmall cell lung cancer ( NSCLC ) refractory solid tumor metastatic unresectable standard curative palliative treatment option available target EGFR may appropriate Measureable disease accord RECIST Version 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Minimum age 18 year Adequate hematological , hepatic renal function Written consent Institutional Review Boardapproved inform consent form prior studyspecific evaluation Phase 2 patient must confirm EGFR T790M mutationpositive NSCLC Active second malignancy prior malignancy treat chemotherapy less equal 6 month prior treatment CK101 History , evidence clinically active , interstitial lung disease Brain metastases unless asymptomatic , stable require steroid least 2 week Treatment prohibit medication Any toxicity relate prior treatment must resolve Grade 1 less , exception alopecia Grade 2 , prior platinumtherapy relate neuropathy Certain cardiac abnormality history Nonstudy relate surgical procedure less equal 14 day prior CK101 administration Females pregnant breastfeeding . Refusal use adequate contraception fertile patient ( female male ) Presence serious unstable concomitant systemic disorder incompatible clinical study Refractory nausea vomiting , chronic gastrointestinal disease , inability swallow formulate product previous significant bowel resection Phase 2 patient also exclude prior treatment CK101 third generation TKIs target EGFR T790M mutationpositive NSCLC , evidence tumor harbor exon 20 insertion mutation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>EGFR sensitivity mutation</keyword>
	<keyword>T790M</keyword>
	<keyword>NSCLC</keyword>
	<keyword>epidermal growth factor receptor</keyword>
	<keyword>EGFR</keyword>
	<keyword>EGFR inhibitor</keyword>
	<keyword>Solid Tumors</keyword>
</DOC>